3.01

5.05% -0.16

After Hours: 3.02 0.01 +0.33%

Perspective Therapeutics Inc (CATX)

Overview News Price History Discussions Forecast Stock Split

Perspective Therapeutics Inc stock is traded at $3.01, with a volume of 2.81M. It is down -5.05% in the last 24 hours and up +2.03% over the past month. Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Previous Close:

$3.17

Open:

$3.18

24h Volume:

2.81M

Relative Volume:

1.67

Market Cap:

$343.28M

Revenue:

$884.00K

Net Income/Loss:

$-103.64M

P/E Ratio:

-2.1586

EPS:

-1.3944

Net Cash Flow:

$-95.45M

1W Performance:

-17.08%

1M Performance:

+2.03%

6M Performance:

+5.99%

1Y Performance:

-26.76%

1-Day Range:

$2.895

$3.19

1-Week Range:

$2.895

$3.77

52-Week Range:

$1.955

$6.16

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name

Perspective Therapeutics Inc

Sector

Healthcare (1096)

Industry

Medical Devices (140)

Phone

509-375-1202

Address

350 Hills Street, Suite 106, Richland

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

CATX's Discussions on Twitter

Compare CATX vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CATX Perspective Therapeutics Inc	3.01	343.28M	884.00K	-103.64M	-95.45M	-1.3944
ABT Abbott Laboratories	93.93	163.61B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	329.78	126.42B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.87	107.36B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.77	66.54B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	92.21	53.09B	6.30B	1.07B	1.09B	1.8406

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	Piper Sandler	Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-10-25	Initiated	BTIG Research	Buy
Mar-13-25	Initiated	H.C. Wainwright	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy
Oct-01-24	Initiated	Wedbush	Outperform
Sep-25-24	Initiated	Truist	Buy
Jul-25-24	Initiated	BofA Securities	Buy
May-09-24	Initiated	Cantor Fitzgerald	Overweight

View All

Perspective Therapeutics Inc Stock (CATX) Latest News

Jul 10, 2026

CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus

Jul 10, 2026

Jul 08, 2026

Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com

Jul 08, 2026

Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com

Jul 08, 2026

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times

Jul 08, 2026

Perspective Therapeutics taps Merck KGaA oncology chief in planned science shift - Stock Titan

Jul 08, 2026

Jul 07, 2026

Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr

Jul 07, 2026

Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr

Jul 07, 2026

Perspective Therapeutics (CATX) Proxy filing Summary - Quartr

Jul 07, 2026

Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr

Jul 07, 2026

Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr

Jul 07, 2026

Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr

Jul 07, 2026

Jul 05, 2026

Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id

Jul 05, 2026

Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance

Jul 05, 2026

Jul 01, 2026

Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart

Jul 01, 2026

Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks

Jul 01, 2026

Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan

Jul 01, 2026

Jun 30, 2026

Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan

Jun 30, 2026

Jun 26, 2026

CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus

Jun 26, 2026

Jun 25, 2026

Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView

Jun 25, 2026

Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

Jun 25, 2026

Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

Jun 25, 2026

CATX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView

Jun 25, 2026